SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: In our study, we found that BAY-293, compared with imatinib, prolonged CML survival in mouse model of imatinib-resistant CML by reducing the activity of SOS1 and upregulating SLC22A4.